GPC3 and cancer: In the case of GPC3, two humanized mAbs (hYP7 and hYP9.1b) in the IgG format have been reported to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in GPC3-positive cancer cells [27].